SCHEMBL6322741

SCHEMBL6322741

N[C@H](C(=O)O)c1ccccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 1/20 0.59
ACP3 P15309 1/20 0.46
IDO1 P14902 2/20 0.44
TDO2 P48775 2/20 0.44
IDO2 Q6ZQW0 2/20 0.44
ALDH1A1 P00352 1/20 0.43
CXCL8 P10145 1/20 0.42
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
GRM1 Q13255 2/20 0.41
AOC3 Q16853 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1159922 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2CYP3A4ACP3
SCHEMBL753104 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2CYP3A4ACP3
SCHEMBL29122982 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2CYP3A4ACP3
SCHEMBL29400420 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2CYP3A4ACP3
SCHEMBL29454486 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2CYP3A4ACP3
Hydrochloric Acid SCHEMBL8015976 0.98 MEN1 (0.58) MEN1KMT2ACYP1A2CYP3A4ACP3
Hydrochloric Acid SCHEMBL8015981 0.98 MEN1 (0.58) MEN1KMT2ACYP1A2CYP3A4ACP3
Hydrochloric Acid SCHEMBL8015977 0.98 MEN1 (0.58) MEN1KMT2ACYP1A2CYP3A4ACP3
SCHEMBL24044801 0.84 MEN1 (0.48) MEN1KMT2ACYP1A2CYP3A4GRM1
SCHEMBL381133 0.84 CYP1A2 (0.55) MEN1KMT2ACYP1A2CYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949658-B2 Process for producing optically active α-amino acid and optically active α-amino acid amide MITSUBISHI RAYON CO., LTD. (JP) 2005-09-27 US claimed
US-20040176637-A1 Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation ROBERT C. C. WU (TW) 2004-09-09 US claimed
US-20030171597-A1 Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine MITSUBISHI RAYON CO., LTD. (JP) 2003-09-11 US claimed
EP-1300392-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE Mitsubishi Rayon Co., Ltd. (JP) 2003-04-09 EP claimed
US-20230279553-A1 Method for Manufacturing Conductive Pattern-Provided Structure ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-09-07 US disclosed
CN-114507650-B Leucine dehydrogenase mutant and application thereof in synthesis of (S) -o-chlorophenylglycine 浙江工业大学 2023-09-05 CN disclosed
EP-4234758-A1 METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE Asahi Kasei Kabushiki Kaisha (JP) 2023-08-30 EP disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
EP-4058465-A1 CXCR4 ANTAGONIST PEPTIDES Cohbar Inc. (US) 2022-09-21 EP disclosed
EP-4013440-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2022-06-22 EP disclosed
CN-114507650-A Leucine dehydrogenase mutant and application thereof in synthesis of (S) -o-chlorophenylglycine 浙江工业大学 2022-05-17 CN disclosed
WO-2022085461-A1 METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE 旭化成株式会社 2022-04-28 WO disclosed
US-20040176637-A1 Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation ROBERT C. C. WU (TW) 2004-09-09 US disclosed
US-20040176637-A1 Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation ROBERT C. C. WU (TW) 2004-09-09 US disclosed
US-20030171597-A1 Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine MITSUBISHI RAYON CO., LTD. (JP) 2003-09-11 US disclosed
EP-0971915-B1 METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES SANOFI SYNTHELABO (FR) 2003-05-14 EP disclosed
EP-1300392-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE Mitsubishi Rayon Co., Ltd. (JP) 2003-04-09 EP disclosed
US-6080875-A REACTING A THIENYLGLYCIDIC DERIVATIVE WITH A PHENYLGLYCINE ESTER IN THE PRESENCE OF AN ALKALI METAL BOROHYDRIDE, DECYCLIZATION; PREPARING DRUGS FOR TREATING ANTI-PLATELET AGGREGATION AND ANTITHROMBOTIC ACTIVITIES SANOFI-SYNTHELABO (FR) 2000-06-27 US disclosed
EP-0971915-A1 METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES SANOFI-SYNTHELABO (FR) 2000-01-19 EP disclosed
WO-1998039322-A1 METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES SANOFI-SYNTHELABO (FR) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176637-A1 Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation SRM, CES2, UGT1A6 MEN1 4810/4885KMT2A 2170/4885CYP1A2 17/4885
US-20030171597-A1 Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine AADAT, BCAT1, BCAT2 MEN1 3310/4885KMT2A 902/4885CYP1A2 1627/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR MEN1 3914/4885KMT2A 4739/4885CYP1A2 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.